Revolution Medicines, Inc. provided earnings guidance for full year 2024. For the year, the company expects GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million. Based on the company?s current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.96 USD | +1.78% | +2.98% | +25.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.38% | 6.13B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024